Lasse Jørgensen Cehofski

Lasse Jørgensen Cehofski serves as a Clinical Associate Professor at Aalborg University within the Faculty of Medicine and Department of Clinical Medicine, concurrently holding a clinical position as department physician (Afdelingslæge) in the Department of Ophthalmology at Aalborg University Hospital. His academic and clinical work focuses on advancing ophthalmological research and patient care through evidence-based approaches.

Dr. Cehofski's research centers on Retinal Vein Occlusion, Diabetic Retinopathy, and Anti-VEGF Therapy, with significant contributions to proteomic biomarker discovery and physiological impact studies. His work bridges clinical practice and academic research, emphasizing systematic reviews and meta-analyses to evaluate treatment efficacy and safety in retinal diseases. Key methodologies include proteomic analysis, network meta-analysis, and clinical epidemiology to address therapeutic challenges in complex eye conditions.

Recent publications (2024-2025) demonstrate a concentrated effort in systematic reviews covering anti-VEGF therapy optimization for macular degeneration, macular edema patterns in uveitis, and proteomic risk stratification for diabetic retinopathy. His research consistently addresses evidence applicability across diverse patient populations, physiological impacts on ocular structures, and biomarker-driven personalized treatment strategies.

Dr. Cehofski has supervised at least one PhD student, with a graduation recorded in 2017. His collaborative research network spans Aalborg University Hospital and international institutions, though specific grant details remain unreported. He maintains active contributions to high-impact ophthalmology journals through peer-reviewed systematic reviews and meta-analyses.

His research operates within Aalborg University's integrated clinical-academic environment, leveraging multidisciplinary collaborations between the Department of Clinical Medicine and Department of Ophthalmology to investigate retinal pathologies and therapeutic innovations through proteomic, physiological, and clinical trial frameworks.